KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Revenue (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Revenue data on record, last reported at -$4.8 million in Q4 2025.

  • For Q4 2025, Revenue fell 102.13% year-over-year to -$4.8 million; the TTM value through Dec 2025 reached $561.5 million, up 17.0%, while the annual FY2025 figure was -$17.3 million, 102.45% down from the prior year.
  • Revenue reached -$4.8 million in Q4 2025 per IONS's latest filing, down from $156.7 million in the prior quarter.
  • Across five years, Revenue topped out at $324.5 million in Q4 2023 and bottomed at -$4.8 million in Q4 2025.
  • Average Revenue over 5 years is $135.9 million, with a median of $133.8 million recorded in 2022.
  • The widest YoY moves for Revenue: up 926566.67% in 2025, down 102.13% in 2025.
  • A 5-year view of Revenue shows it stood at $60.0 million in 2021, then soared by 153.15% to $151.9 million in 2022, then soared by 113.64% to $324.5 million in 2023, then plummeted by 30.18% to $226.6 million in 2024, then tumbled by 102.13% to -$4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were -$4.8 million in Q4 2025, $156.7 million in Q3 2025, and $278.0 million in Q2 2025.